Subash Bazaz, MD
Cardiovascular Disease · Leesburg, VANPI 1619971264
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 134 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$443
- E.r. Squibb & Sons, L.L.C.$276
- Merck$271
- Pfizer$251
- Amgen$246
- Johnson & Johnson$208
- plus $977 from 18 others
Across 32 payments — averaging $12,908 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$150K
- Novartis$140K
- Amgen$82K
- Bayer$37K
- E.r. Squibb & Sons, L.L.C.$5K
What the payments were for
- Food & beverage$2,672100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $443 |
| E.r. Squibb & Sons, L.L.C. | 11 | $276 |
| Merck | 12 | $271 |
| Pfizer | 14 | $251 |
| Amgen | 14 | $246 |
| Johnson & Johnson | 9 | $208 |
| Boston Scientific | 7 | $140 |
| AstraZeneca | 7 | $113 |
| Boehringer Ingelheim | 5 | $110 |
| Alnylam Pharmaceuticals Inc. | 5 | $109 |
| Novo Nordisk | 4 | $95 |
| Sanofi-aventis U.S. LLC | 6 | $89 |
| Esperion Therapeutics, Inc. | 2 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $44 |
| Scpharmaceuticals Inc. | 2 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Recor Medical Inc | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Bayer | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Cvrx, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
How this compares
$2,672 in reported general payments places this provider in the 65th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 258 | $350,170 |
| EntrestoSacubitril/Valsartan | 35 | $60,617 |
| XareltoRivaroxaban | 47 | $59,640 |
| JardianceEmpagliflozin | 29 | $38,536 |
| MultaqDronedarone Hcl | 16 | $33,992 |
| Repatha SureclickEvolocumab | 21 | $33,283 |
| FarxigaDapagliflozin Propanediol | 13 | $21,966 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $10,121 |
| Metoprolol Succinate | 283 | $4,275 |
| Valsartan | 116 | $3,509 |
| Atorvastatin Calcium | 313 | $3,407 |
| Rosuvastatin Calcium | 202 | $3,062 |
| Bisoprolol Fumarate | 103 | $2,633 |
| Ezetimibe | 60 | $2,464 |
| Olmesartan Medoxomil | 70 | $1,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $251 | $350,170258 claims |
| NovartisEntresto | $443 | $60,61735 claims |
| Johnson & JohnsonXarelto | $208 | $59,64047 claims |
| Boehringer IngelheimJardiance | $110 | $38,53629 claims |
| Sanofi-aventis U.S. LLCMultaq | $89 | $33,99216 claims |
| AstraZenecaFarxiga | $113 | $21,96613 claims |
| Esperion Therapeutics, Inc.Nexlizet | $45 | $10,12114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Leesburg
- Ibrahim SaeedLeesburg$23K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
- Cyrus HadadiNorfolk$360K
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Alexander TruesdellFalls Church$167K
- Antonio AbbateCharlottesville$161K
- Christopher OconnorFalls Church$161K
- Roberta ChapmanGloucester$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.